Arrhythmogenic right ventricular dysplasia/cardiomyopathy was first reported as the partial replacement of the right ventricular myocardium by fat or fibrous tissue. In 1965, researchers described the ...

Her favorite projects involve sharing the insights of science and medicine. View Full Profile. Learn about our Editorial Policies. Ametabolic biomarker in an inherited heart disorder called ...

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of ...

The classic ECG findings in arrhythmogenic right ventricular dysplasia are inverted T waves in the right precordial leads (V1-V3) with an epsilon wave after the QRS in lead V1, representing early ...

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics Inc (NASDAQ:TNYA), with a price target of $18.00. This aligns with the strong overall analyst consensus, as ...

The syndrome of ‘exercise-induced arrhythmogenic RV cardiomyopathy’ may easily be overlooked. Sports cardiologists, like orthopaedic specialists, should be prepared to realise that excessive sports ...